ArticleClinical cancer research : an official journal of the American Association for Cancer Research2021

RE-MIND: Comparing Tafasitamab + Lenalidomide (L-MIND) with a Real-world Lenalidomide Monotherapy Cohort in Relapsed or Refractory Diffuse Large B-cell Lymphoma.

Pier Luigi Zinzani et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.